IP Library › Granted Patent US 7,579,377
Granted Patent B2
US 7,579,377 · App. 10/937,612 · Granted Aug 25, 2009

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders

Assignee: Galderma Research & Development
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,579,377
App. No.
10/937,612
Granted
Aug 25, 2009
Kind
B2
Abstract

Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefore, advantageously topically applicable gels, creams or lotions.

Claims (51)

1. A method for treating common acne, comedones, polymorphous acne, nodulocystic acne, acne conglobata or secondary acne afflicting the skin of an individual in need of such treatment, comprising topically administering to said individual a thus effective amount of a pharmaceutical composition which is a gel of:

Adapalene

3

mg

Carbomer 940

11

mg

Disodium edetate

1

mg

Methyl paraben

2

mg

Poloxamer 124

2

mg

Propylene glycol

40

mg

Sodium hydroxide amount required to obtain a pH of

5.0 ± 0.3

and

Purified water

q.s. 1

g.

2. A method for treating common acne afflicting the skin of an individual in need of such treatment, comprising topically administering to said individual a thus effective amount of a pharmaceutical composition which is a gel of:

Adapalene

3

mg

Carbomer 940

11

mg

Disodium edetate

1

mg

Methyl paraben

2

mg

Poloxamer 124

2

mg

Propylene glycol

40

mg

Sodium hydroxide amount required to obtain a pH of

5.0 ± 0.3

and

Purified water

q.s. 1

g.

3. The method according to claim 2 , wherein the common acne is of moderate to moderately severe intensity.

Assignments (2)
CORRECTION OF CORPORATE NAME AND ADDRESS Recorded Aug 20, 2007
From: GALDERMA RESEARCH & DEVELOPMENT, S.N.C. VALBONNE, FRANCE
To: GALDERMA RESEARCH & DEVELOPMENT
Reel/Frame 019720/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2004
From: GRAEBER, MICHAEL; CZERNIELEWSKI, JANUSZ
To: GALDERMA RESEARCH & DEVELOPMENT, S.N.C.
Reel/Frame 015415/0251 →
Priority Claims (1)
FR 02 03070 · Mar 12, 2002 · national
Continuity (3)
Continuation PCTEP030324600 · Mar 12, 2003
Provisional Application 6037022300 · Apr 8, 2002
Related Publication 20050059740A1 · Mar 17, 2005